Onco-Innovations Cash Flow Statement

Financials in millions CAD. Fiscal year is May - April.

Millions CAD. Fiscal year is May - Apr.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023
Period Ending	Jan '26 Jan 31, 2026	Apr '25 Apr 30, 2025	Apr '24 Apr 30, 2024	Apr '23 Apr 30, 2023
Net Income	-14.92	-8.49	-0.39	-0
Asset Writedown & Restructuring Costs	3.66	3.66	-	-
Stock-Based Compensation	5.02	1.73	-	-
Other Operating Activities	0.02	0.16	-	-
Change in Accounts Receivable	-	-0.05	-	-
Change in Accounts Payable	0.23	0.14	0.39	0
Change in Other Net Operating Assets	0.49	-1	-	-
Operating Cash Flow	-5.5	-3.86	-0.01	-0
Cash Acquisitions	0.01	0.1	-	-
Investing Cash Flow	0.01	0.1	-	-
Long-Term Debt Repaid	-	-0.02	-	-
Net Debt Issued (Repaid)	-0.02	-0.02	-	-
Issuance of Common Stock	4.74	4.56	1.35	0.02
Other Financing Activities	-0.13	-0.12	-	-
Financing Cash Flow	4.59	4.42	1.35	0.02
Net Cash Flow	-0.9	0.66	1.34	0.02
Levered Free Cash Flow	-	-1.01	-	-
Unlevered Free Cash Flow	-	-1.01	-	-
Change in Working Capital	0.72	-0.91	0.39	0

Source: S&P Global Market Intelligence. Standard template. Financial Sources.